AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05322902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remimazolam group
Description: Remimazolam 6 mg/kg/hr is administered as an intravenous infusion until the patient loses consciousness. Anesthesia is maintained at 1 mg/kg/hr of remimazolam. After confirming that the eyelash reflex disappears, rocuronium 0.8 mg/kg is administered, and SGA insertion is performed. During maintenance of general anesthesia, the concentration of remifentanil is continuously adjusted so that the ANI is above 50.
Study NCT05322902 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol group
Description: Propofol intravenous infusion is initiated by the application of a target concentration infusion (TCI) pump to cause the patient to lose consciousness. After confirming that the eyelash reflex disappears, rocuronium 0.8 mg/kg is administered, and SGA insertion is performed. During maintenance of general anesthesia, the concentration of remifentanil is continuously adjusted so that the ANI is above 50.
Study NCT00320567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: norgestimate/ethinyl estradiol
Study NCT06327711 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control: CHO Blend
Description: 2 servings as a snack or between meals morning and evening
Study NCT06327711 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: CHO Blend plus AN100
Description: 2 servings as a snack or between meals morning and evening
Study NCT06364878 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: In vivo confocal microscopy
Description: The patients cornea will be examined non-invasively by IVCM
Study NCT06364878 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Tear film sampling
Description: Patients tear film will be collected and stored at -80 degrees for analysis
Study NCT05671250 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PRP gel and SOC-treatment
Description: Platelet-lysate loaded sustained release thermo-gelling formulation
Study NCT05671250 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: EPO/ISDN/UFH cryogel dressing
Description: Erythropoietin/Isosorbide dinitrate loaded cryogel scaffold
Study NCT05671250 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Sharp debridement, saline washing and regular saline dressing
Study NCT05472792 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Accelerated Partial Breast Irradiation (APBI)
Description: Radiation treatment delivered to the lumpectomy cavity.
Study NCT05472792 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tamoxifen, anastrozole, exemestane, letrozole, fulvestrant, toremifene
Description: Adjuvant endocrine therapy (tamoxifen, anastrozole, exemestane, letrozole, fulvestrant, toremifene) for duration of 5 years, as tolerated by the patient.
Study NCT05318508 — intervention group
Intervention type: OTHER
Intervention: Measurements of sagittal spinopelvic parameters
Description: Sagittal spinopelvic parameters will be measured from lateral cervicothoracolumbar radiographs of patients with lower extremity amputation.
Study NCT05710575 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: probiotic
Description: Probiotic or placebo administration will be started from the first feed of the infants. Infants in the probiotic group will receive five drops of oil-based suspension containing 1×108 colony-forming units of L reuteri (DSM 17938 Biogaia AB, Stockholm, Sweden) once a day, until death or discharge from the hospital. For infants on oral feeds, after suctioning oral secretions, five drops will be placed in the posterior oropharynx of the infants. For infants without per oral feeds, five drops will be administered through a gastric tube followed by a flash of 0.5 mL of sterile water. For the infants in the placebo group, five drops from an identical vial containing only oil base will be administered following the same protocol as the probiotic group.
Study NCT05710575 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: Probiotic or placebo administration will be started from the first feed of the infants. Infants in the probiotic group will receive five drops of oil-based suspension containing 1×108 colony-forming units of L reuteri (DSM 17938 Biogaia AB, Stockholm, Sweden) once a day, until death or discharge from the hospital. For infants on oral feeds, after suctioning oral secretions, five drops will be placed in the posterior oropharynx of the infants. For infants without per oral feeds, five drops will be administered through a gastric tube followed by a flash of 0.5 mL of sterile water. For the infants in the placebo group, five drops from an identical vial containing only oil base will be administered following the same protocol as the probiotic group.
Study NCT05238480 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: XC mouthguard
Description: Use of a Xtreme Conventional custom-made mouthguard while playing rugby
Study NCT05238480 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: XP mouthguard
Description: Use of a Xtreme Pro custom-made mouthguard while playing rugby
Study NCT04974450 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Trigona honey
Description: composition : vitamin C 0.15%, Protein 1.32%, lipid 0.23%, carbohydrate 64.12%, beta carotene 10.61 ppm, Calcium 273,23, magnesium 338.94, zinc 12.49 ppm, and acidity 5.76. Total polyphenol 133.52 ppm, total flavonoid 159.62 ppm. This liquid has a sour profile
Study NCT04974450 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: Artificial honey with fructose, Glucose, pure honey (2,271%), citric acid, and lime extract (0,076%).
Study NCT06334549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ephedrine-P
Description: after induction of anesthesia, use total intravenous anesthesia maintained with propofol
Study NCT05006521 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: KN-002
Description: KN-002 dry powder inhaler
Study NCT06101524 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Free gingival unit, free gingival greft
Description: The free gingival graft and the free gingival unit taken from the upper jaw palatal mucosa were sutured to the lower jaw anterior region.
Study NCT06334549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine-P
Description: after induction of anesthesia, use total intravenous anesthesia maintained with propofol
Study NCT06334549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine-P
Description: after induction of anesthesia, use total intravenous anesthesia maintained with propofol
Study NCT06334549 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ephedrine-S
Description: after induction of anesthesia, use inhalation anesthesia maintained with sevoflurane
Study NCT06616948 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Cycling Group
Description: engaged with a research staff member for 30 minutes of cycling
Study NCT06616948 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: coaching calls
Description: individuals will receive a phone call every 14 days to discuss ongoing exercise maintenance efforts.
Study NCT06616948 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No coaching calls
Description: Following completion of the 6-month cycling sessions, no maintenance calls will be placed.
Study NCT03992950 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maneuvers for occluding esophagus
Description: Cricoid pressure: pressure on the cricoid ring Paratracheal pressure: pressure on the left paratracheal region below the cricoid level
Study NCT04796584 — intervention group
Intervention type: OTHER
Intervention: Analysis of cell-mediated and antibody-mediated immunity to SARS-CoV-2 virus
Description: mRNA vaccination for SARS-CoV-2 is not provided by the study
Study NCT06334549 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine-S
Description: after induction of anesthesia, use inhalation anesthesia maintained with sevoflurane
Study NCT06334549 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine-S
Description: after induction of anesthesia, use inhalation anesthesia maintained with sevoflurane
Study NCT05381480 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In-home Preventive Health Visits by Advanced Practice Nurse
Description: Elements of Comprehensive Geriatric Assessment used as a preventive, health risk assessment, with recommendations tailored for health risks identified and offered to building tenants
Study NCT05381480 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: On-site Evidence-based Physical Activity, Health and Wellness Classes
Description: Weekly calendar of health promotion and injury/illness prevention classes offered to building tenants.
Study NCT04811690 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: front-of-package modification
Description: testing front-of-package changes to claims, imagery, disclosures, and added sugar warning labels on fruit-flavored drinks
Study NCT05076058 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tablet of silybum marianum, Pueraria lobate and salvia miltiorrhiza
Description: Brand names: BY-HEALTH；~Main contents (per 100g): silibinin 2g, salvianolic acid B 0.72g，Puerarin 0.68g
Study NCT05076058 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: Brand names: BY-HEALTH；~Main contents : starch
Study NCT06492070 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Undergo standard of care
Study NCT06492070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol
Description: Given PO
Study NCT06492070 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryocompression Therapy
Description: Undergo cryocompression therapy
Study NCT06492070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given by infusion
Study NCT06492070 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT06492070 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT05068362 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Auricular reconstruction
Description: Medpor implant for treatment of microtia
Study NCT06553261 — intervention group
Intervention type: PROCEDURE
Intervention: suturing of leak, lavage, drainage
Description: Operative suturing of the leak, lavage, drainage within a revision surgery.
Study NCT06553261 — intervention group
Intervention type: PROCEDURE
Intervention: Formation of a new anasthomosis
Description: Operative resection of the old leaking anastomosis and formation of a new one.
Study NCT06553261 — intervention group
Intervention type: PROCEDURE
Intervention: Fecal diversion
Description: Formation of a deviating stoma.
Study NCT04975945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftriaxone Sodium
Description: Intravenous vs local action
Study NCT04975945 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftriaxone Sodium
Description: Intravenous vs local action
Study NCT06307301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept Injection [Orencia] and Proleukin (aldesleukin)
Description: Abatacept (Orencia®) and recombinant human IL-2 (aldesleukin). Patients will receive a fixed dose of subcutaneous abatacept (125 mg/mL) at day 1. Two weeks later (day 15), patients will receive the second dose of subcutaneous abatacept (125 mg/mL). In addition, patients will receive subcutaneous IL-2 (1x106units /day) for 5 days (days 15-19). If this treatment regimen is tolerated, patients will receive 28 further similar treatment courses of abatacept and IL-2 every two weeks.
Study NCT05705388 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: POSE2.0 Endoscopic Gastric Remodeling
Description: The POSE2.0 is a per-oral endoscopic gastroplasty procedure performed by the USGI Medical Incisionless Operating Platform (USGI Medical, San Clemente, CA) to deploy preloaded snowshoe suture anchors, and cinch create gastric endoscopic plications. In the POSE2.0 procedure a series of 15-20 pairs of snowshoes anchors are deployed along the greater curvature of the stomach from the proximal antrum to the proximal gastric body along narrowing the anteroposterior diameter of the stomach and decreasing its vertical length to improve satiety and satiation for weight loss. This device is registered and approved for obesity management in the United Arab Emirates, where the study is performed.
Study NCT05705388 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide injection
Description: Liraglutide is a GLP-1 agonists approved for the management of obesity. In the study, it will be Initiated at 0.6 mg subcutaneously daily for 1 week; increase by 0.6 mg/day in weekly intervals until a dose of 3 mg/day achieved. If patients do not tolerate an increased dose during dose escalation, dose escalation will be delayed for an additional week. The patient will continue at the maximal tolerated does up to 3mg per day. If the patient has not lost at least 4% of baseline body weight at 16 weeks from medication initiation, the medication will be discontinued.
Study NCT04876911 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simulated Presence Therapy
Description: A video recording of a loved one is played (via an iPad) prior to or during periods where a participant is presenting with stressed/distressed behaviours.
Study NCT05197556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSG4112
Description: Once-daily oral administration
Study NCT05197556 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once-daily oral administration
Study NCT06143644 — intervention group
Intervention type: OTHER
Intervention: Serial ctDNA monitoring
Description: Baseline blood samples, surgical resected tumor tissue, blood samples after surgery (D5-7), blood samples before adjuvant therapy and blood samples after adjuvant therapy (every 3 months for up to 2 years follow-up) will be collected from colorectal patients.
Study NCT05877391 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: SGM Communication Intervention
Description: Evaluate the feasibility and acceptability of the SGM communication intervention by hospice staff. I will pilot test the training with hospice staff to refine the content and delivery of the training. Outcomes in the pilot clinical trial will include feasibility, acceptability, and staff satisfaction with training.
Study NCT06217302 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sotagliflozin
Description: Oral sotagliflozin (200 mg per day)
Study NCT06217302 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive tablets identical to sotagliflozin tablets
Study NCT05230498 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: anatomy-based fitting then default fitting
Description: Cochlear implant with anatomy-based fitting then default fitting
Study NCT05230498 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: default fitting then anatomy-based fitting
Description: Cochlear implant with anatomy-based fitting then default fitting
Study NCT06268899 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: First mobilization protocol
Description: The protocol phases start one day before the patient's surgery and end on the first day of mobilization after surgery. The investigator explains the protocol steps to the patient before surgery and the patient is mobilized within the first 24 hours after surgery. Perform the protocol 4 times a day and more as tolerated. Mobilization protocol: Level 1: Patient is informed about mobilization and readiness is reinforced. Level 2: Passive and active ROM movements in bed should be performed at least 3 times a day. Level 3: Head of bed >60 degrees when the patient is sitting in bed. Duration target: 10-15 minutes. Level 4: Patient is seated on the edge of the bed. Duration target: 10-15 minutes. Level 5: The patient is helped to stand up. Level 6: First mobilization is achieved by allowing the patient to take 10-15 steps. The patient can mobilize at least 4 times a day.
Study NCT06447545 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Changing pressure of Pneumoperitoneum to 6-10 mmHg
Description: Result of changing pneumoperitoneum pressure on CBD injury and pain
Study NCT06447545 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Changing pressure of Pneumoperitoneum to 12-15 mmHg
Description: Result of changing pneumoperitoneum pressure on CBD injury and pain
Study NCT04863417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07038124 or vehicle
Description: PF-07038124 0.01% or vehicle Ointment QD applied to 2000 cm2 Body Surface Area
Study NCT04863417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07038124 or vehicle
Description: PF-07038124 0.01% or vehicle Ointment QD applied to 4000 cm2 Body Surface Area
Study NCT05283889 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Genicular Radiofrequency Ablation
Description: After the cannulae are placed and tines deployed, a single lesion (30 second ramp-up time; 80C x 2 minutes) will be made at each of the medial and lateral branches of the nerve to the vastus intermedialis, nerves to the vastus lateralis and medialis, recurrent fibular nerve, inferior medial genicular nerve. One bipolar strip lesion (intercannula distance 1.5 cm; anticipated strip lesion length 2.0 cm) at the superior medial and lateral genicular nerves will be made to accommodate anatomical variability.
Study NCT05283889 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sham Genicular Radiofrequency Ablation
Description: After the cannulae are placed and tines deployed, a single lesion (no electrical signal applied to patient) will be made at each of the medial and lateral branches of the nerve to the vastus intermedialis, nerves to the vastus lateralis and medialis, recurrent fibular nerve, inferior medial genicular nerve. One bipolar strip lesion (intercannula distance 1.5 cm; anticipated strip lesion length 2.0 cm) at the superior medial and lateral genicular nerves will be made to accommodate anatomical variability.
Study NCT05949606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SI-B001
Description: Administration by intravenous infusion
Study NCT05949606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SI-B003
Description: Administration by intravenous infusion
Study NCT02579187 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tooth extraction
Description: The study tooth will be removed
Study NCT05135728 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unstuck and On Target: Preschool
Description: Unstuck \& On Target: Preschool (UOT:P) is a group-based curriculum for preschool and kindergarten students that targets executive function skills using CBT techniques. The UOT-P curriculum consists of 16 child small-group or classroom-wide lessons. Each lesson follows a clear structure in which the theme for the session is introduced in a storybook, supported with manipulatives and visuals. Children implement the skills introduced in the storybook through joing play activities that require them to flexibly adjusting their plans to work together. Children learn key vocabulary and active coping and problem-solving skills, with adult modeling and scaffolding, that enable them to build early executive functioning skills for self-regulation and classroom participation.
Study NCT05135728 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Unstuck and On Target: Preschool
Description: Unstuck \& On Target: Preschool (UOT:P) is a group-based curriculum for preschool and kindergarten students that targets executive function skills using CBT techniques. The UOT-P curriculum consists of 16 child small-group or classroom-wide lessons. Each lesson follows a clear structure in which the theme for the session is introduced in a storybook, supported with manipulatives and visuals. Children implement the skills introduced in the storybook through joing play activities that require them to flexibly adjusting their plans to work together. Children learn key vocabulary and active coping and problem-solving skills, with adult modeling and scaffolding, that enable them to build early executive functioning skills for self-regulation and classroom participation.
Study NCT05024552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Description: Gilteritinib is an oral inhibitor of FLT3-ITD and FLT3-TKD. Dose cohort 1 will receive 120mg daily on days 6-19 of induction and days 4-17 of re-induction and consolidation
Study NCT05024552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vyxeos
Description: Vyxeos is a liposomal encapsulation of cytarabine and daunorubicin. It is given as an intravenous infusion over 90 minutes on days 1, 3 and 5 of induction and days 1 and 3 of re-induction and consolidation. The induction and reinduction dose is 44mg/m2 daunorubicin and 100mg/m2 of cytarabine with each infusion. The consolidation dose is 29mg/m2 daunorubicin and 65mg/m2 of cytarabine with each dose.